Skip to main content

Table 3 Incidence of chemotherapy-induced thrombocytopenia, by chemotherapy agenta

From: Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice

  Incidence Proportion (95% CI)
All Agents Carboplatin Cisplatin Cyclophosphamide Fluorouracil Gemcitabine Oxaliplatin Vincristine
Evidence of Primary, Secondary, Unspecified Thrombocytopenia and/or Bleeding Events, Receipt of TPOs, or Platelets During Chemotherapy
 Course (n = 215,508) (n = 60,966) (n = 22,393) (n = 83,665) (n = 42,970) (n = 6617) (n = 33,822) (n = 14,610)
  Overall 9.7 (9.6–9.8) 13.2 (12.9–13.5) 9.9 (9.5–10.3) 6.1 (5.9–6.3) 10.9 (10.6–11.2) 13.5 (12.7–14.3) 11.4 (11.1–11.8) 9.6 (9.1–10.1)
  Inpatient 3.0 (2.9–3.1) 4.2 (4.1–4.4) 4.3 (4.1–4.6) 1.6 (1.5–1.7) 3.0 (2.9–3.2) 5.5 (4.9–6.0) 2.9 (2.7–3.1) 3.5 (3.2–3.8)
  Outpatient 6.7 (6.6–6.8) 9.0 (8.7–9.2) 5.6 (5.3–5.9) 4.5 (4.3–4.6) 7.9 (7.6–8.1) 8.0 (7.4–8.7) 8.5 (8.2–8.8) 6.1 (5.7–6.5)
 All Cycles (n = 988,195) (n = 251,611) (n = 67,304) (n = 435,897) (n = 210,734) (n = 22,310) (n = 179,105) (n = 57,387)
  Overall 2.8 (2.8–2.9) 4.2 (4.2–4.3) 4.1 (3.9–4.2) 1.5 (1.5–1.5) 3.2 (3.1–3.3) 5.2 (4.9–5.5) 3.3 (3.2–3.4) 3.2 (3.1–3.4)
  Inpatient 0.7 (0.7–0.7) 1.1 (1.0–1.1) 1.5 (1.4–1.6) 0.3 (0.3–0.3) 0.6 (0.6–0.7) 1.7 (1.5–1.9) 0.6 (0.5–0.6) 0.9 (0.9–1.0)
  Outpatient 2.1 (2.1–2.2) 3.2 (3.1–3.2) 2.6 (2.4–2.7) 1.2 (1.1–1.2) 2.6 (2.5–2.6) 3.5 (3.2–3.7) 2.7 (2.7–2.8) 2.3 (2.2–2.4)
 Cycle 1 (n = 215,508) (n = 60,966) (n = 22,393) (n = 83,665) (n = 42,970) (n = 6617) (n = 33,822) (n = 14,610)
  Overall 2.7 (2.6–2.8) 3.9 (3.7–4.0) 3.7 (3.5–4.0) 1.7 (1.6–1.8) 2.0 (1.9–2.2) 7.0 (6.4–7.6) 1.5 (1.4–1.7) 4.1 (3.8–4.4)
  Inpatient 1.0 (1.0–1.0) 1.4 (1.4–1.5) 1.7 (1.5–1.9) 0.6 (0.5–0.6) 0.7 (0.6–0.8) 3.0 (2.6–3.5) 0.5 (0.4–0.6) 1.5 (1.3–1.7)
  Outpatient 1.7 (1.7–1.8) 2.4 (2.3–2.6) 2.0 (1.9–2.2) 1.2 (1.1–1.2) 1.3 (1.2–1.4) 4.0 (3.5–4.4) 1.0 (0.9–1.1) 2.6 (2.3–2.8)
 Cycle 2 (n = 186,607) (n = 51,796) (n = 17,777) (n = 76,661) (n = 36,785) (n = 4255) (n = 29,562) (n = 11,552)
  Overall 2.7 (2.6–2.8) 3.7 (3.6–3.9) 3.9 (3.6–4.2) 1.4 (1.4–1.5) 2.9 (2.8–3.1) 5.1 (4.4–5.7) 2.5 (2.3–2.7) 3.0 (2.7–3.3)
  Inpatient 0.8 (0.7–0.8) 1.0 (0.9–1.1) 1.4 (1.2–1.6) 0.3 (0.2–0.3) 1.0 (0.9–1.1) 1.4 (1.1–1.8) 0.7 (0.6–0.8) 0.8 (0.7–1.0)
  Outpatient 1.9 (1.9–2.0) 2.7 (2.6–2.8) 2.5 (2.3–2.7) 1.2 (1.1–1.3) 2.0 (1.8–2.1) 3.7 (3.1–4.2) 1.8 (1.6–1.9) 2.1 (1.9–2.4)
 Cycle 3+ (n = 586,080) (n = 138,849) (n = 27,134) (n = 275,571) (n = 130,979) (n = 11,438) (n = 115,721) (n = 31,225)
  Overall 2.9 (2.9–3.0) 4.6 (4.5–4.7) 4.4 (4.2–4.7) 1.4 (1.4–1.5) 3.7 (3.6–3.8) 4.1 (3.8–4.5) 4.0 (3.9–4.1) 2.9 (2.7–3.1)
  Inpatient 0.5 (0.5–0.6) 0.9 (0.9–1.0) 1.4 (1.2–1.5) 0.3 (0.2–0.3) 0.5 (0.5–0.5) 1.0 (0.8–1.2) 0.5 (0.5–0.6) 0.7 (0.6–0.8)
  Outpatient 2.4 (2.3–2.4) 3.7 (3.6–3.8) 3.0 (2.8–3.3) 1.2 (1.1–1.2) 3.1 (3.1–3.2) 3.1 (2.8–3.4) 3.5 (3.4–3.6) 2.2 (2.0–2.3)
  1. aOnly first eight cycles were considered in analyses described herein; agent-specific subgroups are not mutually exclusive